AI assistant
LIGAND PHARMACEUTICALS INC — Director's Dealing 2017
May 16, 2017
31289_dirs_2017-05-15_b8929439-8f18-4d31-a037-e200bcc13578.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2017-05-12
Reporting Person: FOEHR MATTHEW W (President and COO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-05-12 | Common Stock | M | 5621 | $9.97 | Acquired | 98341 | Direct |
| 2017-05-12 | Common Stock | S | 5621 | $112.1954 | Disposed | 92720 | Direct |
| 2017-05-15 | Common Stock | M | 2200 | $9.97 | Acquired | 94920 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-05-12 | Employee Stock Option (right to buy) | $9.97 | M | 5621 | Disposed | 2021-04-18 | Common Stock (5621) | Direct |
| 2017-05-15 | Employee Stock Option (right to buy) | $9.97 | M | 2200 | Disposed | 2021-04-18 | Common Stock (2200) | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.90 to $112.25, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 04/18/11.